Evidence map›Paper›PMID 41349854›Full record

ArticleAmerican journal of ophthalmology2026

ChatGPT-Assisted Glaucoma Diagnosis: A Health-Equitable Multi-Ancestry Analysis Using Visual Field and Optical Coherence Tomography Data.

Andy S Huang, Anthony Fam, Hetince Zhao, Nicole Paulescu, Anna Fabczak-Kubicka, Janey L Wiggs, Nazlee Zebardast, David S Friedman, Ron Do, Kanza Aziz and 7 more

Abstract read
In one paragraph

Article in American journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Andy S HuangFrom the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai (A.S.H., A.F., H.Z., N.P., A.F.-K., A.H., T.Y.T.T., J.C.T., L.R.P.), New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA. Electronic address: andyshihuang@gmail.com.
Anthony FamFrom the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai (A.S.H., A.F., H.Z., N.P., A.F.-K., A.H., T.Y.T.T., J.C.T., L.R.P.), New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA.
Hetince ZhaoFrom the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai (A.S.H., A.F., H.Z., N.P., A.F.-K., A.H., T.Y.T.T., J.C.T., L.R.P.), New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA.
Nicole PaulescuFrom the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai (A.S.H., A.F., H.Z., N.P., A.F.-K., A.H., T.Y.T.T., J.C.T., L.R.P.), New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA.
Anna Fabczak-KubickaFrom the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai (A.S.H., A.F., H.Z., N.P., A.F.-K., A.H., T.Y.T.T., J.C.T., L.R.P.), New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA.
Janey L WiggsDepartment of Ophthalmology, Massachusetts Eye and Ear (J.L.W., N.Z., D.S.F., K.A., T.E., M.W.), Harvard Medical School, Boston, Massachusetts, USA.
Nazlee ZebardastDepartment of Ophthalmology, Massachusetts Eye and Ear (J.L.W., N.Z., D.S.F., K.A., T.E., M.W.), Harvard Medical School, Boston, Massachusetts, USA.
David S FriedmanDepartment of Ophthalmology, Massachusetts Eye and Ear (J.L.W., N.Z., D.S.F., K.A., T.E., M.W.), Harvard Medical School, Boston, Massachusetts, USA.
Ron DoThe Charles Bronfman Institute for Personalized Medicine (R.D.), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Kanza AzizDepartment of Ophthalmology, Massachusetts Eye and Ear (J.L.W., N.Z., D.S.F., K.A., T.E., M.W.), Harvard Medical School, Boston, Massachusetts, USA.
Jae Hee KangChanning Division of Network Medicine, Department of Medicine (J.H.K.), Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Tobias ElzeDepartment of Ophthalmology, Massachusetts Eye and Ear (J.L.W., N.Z., D.S.F., K.A., T.E., M.W.), Harvard Medical School, Boston, Massachusetts, USA.
Mengyu WangDepartment of Ophthalmology, Massachusetts Eye and Ear (J.L.W., N.Z., D.S.F., K.A., T.E., M.W.), Harvard Medical School, Boston, Massachusetts, USA.
Alon HarrisFrom the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai (A.S.H., A.F., H.Z., N.P., A.F.-K., A.H., T.Y.T.T., J.C.T., L.R.P.), New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA.
Tak Yee Tania TaiFrom the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai (A.S.H., A.F., H.Z., N.P., A.F.-K., A.H., T.Y.T.T., J.C.T., L.R.P.), New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA.
James C TsaiFrom the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai (A.S.H., A.F., H.Z., N.P., A.F.-K., A.H., T.Y.T.T., J.C.T., L.R.P.), New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA.
Louis R PasqualeFrom the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai (A.S.H., A.F., H.Z., N.P., A.F.-K., A.H., T.Y.T.T., J.C.T., L.R.P.), New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA.

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Understanding the clinical impact of cumulative genetic risk to glaucomaR01EY032559 · NEI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Louis Robert Pasquale, Janey L Wiggs · 2021 to 2026
$4.3M
Multiomic Framework for GlaucomaR01EY036460 · NEI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JAE H KANG, Louis Robert Pasquale · 2024 to 2026
$2.4M
Personalizing Glaucoma Diagnosis by Disease Specific Patterns and Individual Eye AnatomyR01EY030575 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI ELZE, TOBIAS · 2019 to 2023
$2.4M
SCH: SEEthroughGLAUCOMA: Smart Eye Emulator (SEE) to study glaucoma risk factorsR01EY034718 · NEI · UNIVERSITY OF MAINE ORONO · PI GUIDOBONI, GIOVANNA, HARRIS, ALON · 2022 to 2025
$975k
Personalizing Circumpapillary Retinal Nerve Fiber Layer Thickness Norms for GlaucomaR21EY035298 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI WANG, MENGYU · 2023 to 2023
$557k
NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY030575NEI NIH HHS R01 EY032559NEI NIH HHS R01 EY034718NEI NIH HHS R01 EY036460NEI NIH HHS R21 EY035298
6 · The paper itself

Abstract

purposeEarly glaucoma detection is challenging due to variable ocular anatomy, non-glaucomatous optic neuropathy impacting optical coherence tomography (OCT) results, and the subjective nature of visual field (VF) tests. Multimodal large language models may overcome these challenges to provide equitable and accurate screening diagnoses across ancestries and glaucoma genetic predispositions. We evaluated ChatGPT o1 Pro's accuracy in identifying glaucoma using circumpapillary retinal nerve fiber layer (RNFL) OCT and VF data, and its consistency across ancestries and glaucoma polygenic risk scores (PRS).

designCross-sectional diagnostic accuracy study. SETTINGS AND

participantsWe enrolled 204 participants from the Mount Sinai BioMe Biobank for a comprehensive ophthalmic examination from November 2022 to March 2025. This cross-sectional diagnostic accuracy study included 38% European (EUR) and 62% non-European (non-EUR) participants stratified by low/intermediate (n = 107) and high-risk glaucoma PRS (n = 97). Two glaucoma specialists masked to PRS status provided a consensus reference diagnosis. ChatGPT received only de-identified VFs and OCT-RNFL numerical outputs to determine glaucoma status. Performance metrics were compared with the reference diagnosis. Subgroup comparisons by ancestry (EUR versus non-EUR) and PRS (high versus low/intermediate) were conducted. We used logistic regression models to assess the impacts of ancestry, PRS and ocular parameters on classification accuracy.

main outcome measuresChatGPT o1 Pro's diagnostic performance in detecting glaucoma compared to consensus specialist diagnoses, stratified by ancestry and genetic risk.

resultsChatGPT o1 Pro exhibited 96.0% sensitivity (95% confidence interval (CI): 88.3%-100%), 83.7% specificity (95% CI: 78.3%-89.1%), 85.2% accuracy (95% CI: 80.3%-90.1%), an area under the receiver operator curve (AUC) of 0.899, a positive predictive value (PPV) of 45.3% (95% CI: 31.9%-58.7%), and a negative predictive value (NPV) of 99.3% (95% CI: 98.0%-100%); κ for agreement with the consensus reference was 0.538. No significant differences were observed between EUR and non-EUR subgroups (AUC: 0.894 vs 0.906, P = .79; accuracy: 88.3% vs 83.3%, P = .44) or high and low/intermediate-PRS subgroups (AUC: 0.889 vs 0.922, P = .45; accuracy: 85.4% vs 85.0%, P = .50). Global RNFL was the only determinant of reference disease classification (OR = 1.1 per micron, P < .001).

conclusionChatGPT o1 Pro diagnosed glaucoma similarly to specialists using only VF and OCT data. The model performance was similar across ancestral groups and genetic predispositions to glaucoma.

Indexed as

GlaucomaTomography, Optical CoherenceVisual FieldsAdultAgedCross-Sectional StudiesFemaleGenerative Artificial IntelligenceHumansIntraocular PressureMaleMiddle AgedNerve FibersOptic DiskReproducibility of ResultsRetinal Ganglion Cells

Identifiers

PMID41349854
PMCPMC12698116

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.